An open-label study followed by a double-blind randomised comparison of the effect of sedation versus melatonin combined with sedation in children undergoing magnetic resonance imaging (MRI)

Completed

Conditions: ot Applicable: Magnetic resonance imaging (MRI)
Not Applicable
Magnetic resonance imaging (MRI)

Registration Number: ISRCTN13459412

Lead Sponsor: Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Children undergoing MRI

Exclusion Criteria

Not provided at time of registration

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Study of Koflet in Cough

Phase 2

Himalaya Wellness Company

Updated 5/27/2024

Ayurveda management of ARTAVA KSHAYA w.s.r to PCOS

Phase 2

DrBharathi K S

Updated 5/27/2024

A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

Phase 1

Galecto Biotech AB

Updated 8/28/2023

The purpose of this study is to evaluate a drug (LUM001 also known as SHP625) that may help treat the liver and control itching in Alagille Syndrome. In the Optional Follow-up Treatment Period (after Week 48), all eligible children treated in the LUM001-304 study will be offered to continue the study drug treatment until the subjects are eligible to enter another LUM001 study or LUM001 is available commercially, or the sponsorstops the program or development in this indication.

Phase 1

Mirum Pharmaceuticals, Inc.

Updated 10/13/2020

The purpose of this study is to evaluate a drug (LUM001) that may help treat the liver and control itching in Alagille Syndrome. In this study, all children who are eligible to enrol will take study drug for 18 weeks, followed by a 4 week period where they will either take LUM001 or placebo. After this 4 week period, all patients will go back on active study drug treatment for the remaining 26 weeks.

Phase 1

umena Pharmaceuticals Inc

Updated 9/28/2020

The purpose of this study is to evaluate a drug (LUM001 also known as SHP625) that may help treat the liver and control itching in Alagille Syndrome. In the Optional Follow-up Treatment Period (after Week 48), all eligible children treated in the LUM001-304 study will be offered to continue the study drug treatment until the subjects are eligible to enter another LUM001 study or LUM001 is available commercially, or the sponsorstops the program or development in this indication.

Phase 1

Mirum Pharmaceuticals,Inc.

Updated 11/9/2020

The purpose of this study is to evaluate a drug (LUM001) that may help treat the liver and control itching in Alagille Syndrome. In this study, all children who are eligible to enrol will take study drug for 18 weeks, followed by a 4 week period where they will either take LUM001 or placebo. After this 4 week period, all patients will go back on active study drug treatment for the remaining 26 weeks.

Phase 1

umena Pharmaceuticals Inc

Updated 10/8/2021

The purpose of this study is to evaluate a drug (LUM001) that may help treat the liver and control itching in Alagille Syndrome. In this study, all children who are eligible to enrol will take study drug for 18 weeks, followed by a 4 week period where they will either take LUM001 or placebo. After this 4 week period, all patients will go back on active study drug treatment for the remaining 26 weeks.

Phase 1

umena Pharmaceuticals LLC

Updated 9/28/2020

Pozelimab and Cemdisiran Combination Treatment in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Phase 1

Regeneron Pharmaceuticals, Inc.

Updated 5/17/2021

This is a study to help understand how dulaglutide compares to placebo (a shot that does not contain any active medicine) in children and teens (ages 10 to 17) with type 2 diabetes who may also be taking metformin and long-acting insulin (basal).

Phase 1

Eli Lilly and Company

Updated 2/1/2022

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy